Karin Bhatt

Karin Bhatt investigates NTRK gene fusions in pediatric cancers at the NCI Pediatric Oncology Branch, contributing to the development of TRK inhibitors for this molecularly defined population. She contributed to the clinical studies of larotrectinib and entrectinib in pediatric patients with NTRK fusion-positive solid tumors, supporting their tumor-agnostic FDA approval. Her work has advanced the application of precision medicine to pediatric oncology based on molecular driver alterations. She has led pediatric basket trials testing TRK and other kinase inhibitors across tumor histologies.